Explore chapters and articles related to this topic
Phosphorylation of Phosphofructokinase — The Possible Role of Covalent Modification in the Regulation of Glycolysis
Published in Rivka Beitner, Regulation of Carbohydrate Metabolism, 1985
Fructose-2,6-bisphosphate was shown to be formed by the action of an enzyme called fructose-6-phosphate-2-kinase96 or phosphofructokinase-295 in order to distinguish this enzyme from the phosphofructokinase acting in the glycolytic pathway. Fructose-6-phosphate-2-kinase was effectively inactivated by the administration of glucagon or epinephrine.96,148 It was also inhibited in vitro by the action of the catalytic subunit of cAMP-dependent protein kinase in the presence of ATP. In contrast to the phosphofructokinase acting in glycolysis, phosphorylation of fructose-6-phosphate-2-kinase caused an effective down-regulation of enzyme activity. There was also evidence for the activation of fructose-2,6-bisphosphatase by phosphorylation,96 and it was concluded that the levels of fructose-2,6-bisphosphate in tissue can be effectively regulated by phosphorylation-dephosphorylation mechanisms.96 In combination with a decreased affinity of the phosphorylated phosphofructokinase for fructose-2,6-bisphosphate these mechanisms could provide an efficient regulation of one of the key points of carbohydrate metabolism in liver.
PFKFB3 downregulation aggravates Angiotensin II-induced podocyte detachment
Published in Renal Failure, 2023
Xiaoxiao Huang, Zhaowei Chen, Zilv Luo, Yiqun Hao, Jun Feng, Zijing Zhu, Xueyan Yang, Zongwei Zhang, Jijia Hu, Wei Liang, Guohua Ding
The homodimeric and bifunctional enzyme family of phosphofructokinase-2/Fructose-2,6-bisphosphatase (PFK-2/PFKFB) promotes glycolysis by increasing levels of fructose-2,6-bisphosphate (F2,6P2), which in turn activates the key rate-limiting enzyme 6-phosphofructo-1-kinase (PFK-1) and enhances the conversion of fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (F1,6P2) in the glycolytic pathway. This causes increased glycolytic flux and increased ATP and NADH production [16]. Among the PFKFB family of four enzymes (PFKFB1-4), PFKFB3 has the highest ratio of kinase to phosphatase activity, which ensures a high glycolytic rate [17]. Recent findings have indicated that PFKFB3 exerts protective effects on the kidneys [18] and promotes the activation of cyclin-dependent kinase-1(cdk1) [19], which promotes talin1 phosphorylation [20]. Excessive talin1 phosphorylation promotes integrin beta1 subunit (ITGB1) activity on the cell surface [21]. Active ITGB1 is an important adhesion molecule on the surface of podocytes, and its activation enhances podocyte adhesion capacity [22–25]. Inhibiting PFKFB3 significantly reduces the expression of cell adhesion molecules, resulting in diminished cell adhesion [26–29]. Therefore, we speculated that Ang II could inhibit talin1 phosphorylation and ITGB1 activation through downregulating PFKFB3 expression. Therefore, we investigated the role of PFKFB3 in Ang II-induced podocyte injury and identified a novel target for CKD treatment.
Growth factor signaling pathways in vascular development and disease
Published in Growth Factors, 2019
VEGFA also promotes sprouting angiogenesis through modulation of EC metabolism. ECs in growing vascular networks increase their rates of glycolysis to meet the energy needs required for migration and proliferation (De Bock, Georgiadou, and Carmeliet 2013). VEGFA induces the expression of glycolytic pathway genes including the glucose transporter GLUT1 and the glycolytic enzymes phosphofructokinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3) and lactate dehydrogenase A (LDHA) (De Bock et al. 2013; Parra-Bonilla et al. 2010; Yeh, Lin, and Fu 2008). FGF2 signaling via FGFR1 and FGFR3 also promotes glycolysis during angiogenesis. FGF2 signaling increases the expression of Myc, a driver of cell growth and proliferation, which in turn upregulates another glycolytic pathway enzyme, hexokinase 2 (HK2) (Yu et al. 2017). Mice lacking endothelial PFKFB3 or HK2 have reduced angiogenic vessel growth due to defects in EC proliferation and motility (De Bock et al. 2013; Yu et al. 2017). Lowering both glycolysis and mitochondrial respiration is necessary to reestablish EC quiescence (Wilhelm et al. 2016) demonstrating that metabolic control is, therefore, a key mechanism by which growth factors regulate sprouting angiogenesis.
Redox-sensitive transcription factors play a significant role in the development of rheumatoid arthritis
Published in International Reviews of Immunology, 2018
Scott Le Rossignol, Natkunam Ketheesan, Nagaraja Haleagrahara
RA synovial fluid is hypoxic, acidic, lower in glucose concentration, higher in lactate, acetate, and carbon dioxide concentrations compared to non-rheumatoid synovial fluid [25,48]. Suggestive of utilization of anaerobic metabolism in the synovial environment. Indeed, hypoxia alters RA FLS from a resting state to a metabolically active state, which is achieved by downregulating mitochondrial respiration and promoting glycolysis. This active state is required to drive acilitates proliferation and maturation in the synovium [39]. T cells in RA have a uncoordinated glycolytic pathway, referred to as the Warburg effect, with a shift to the pentose phosphate pathway (PPP) promoting reductive stress on the cell due to increases in NADPH [49]. This lack of co-ordination has been attributed to insufficient induction of 6-phosphofructokinase-2-kinase/fructose-2,6-bisphophatase 3 [49]. The presence of immune complexes in the synovium facilitates migration and proliferation of leukocytes. Leukocytes rely on aerobic metabolism and an increased number in the synovium results in local hypoxia [50]. Synovial hyperproliferation and high metabolic demand of inflamed synovial tissue compounds this hypoxia and only the cells closest to the blood vessel have adequate oxygen 47. Hypoxia and pro-inflammatory cytokines drive production of ROS and RNS from macrophages and neutrophils [11]. In RA, the endothelium is dysfunctional with inadequate tissue oxygen homeostasis and results in hypoxic-reperfusion injury [47]. The degree of hypoxia in synovium correlates with an increased frequency of mitochondrial DNA mutations occurring in response to increased levels of ROS [51]. Mitochondrial mutagenesis resulting in decreased expression of cytochrome C, an oxygen sensor, leading to dysregulated production of ROS [32,51]. TLR2 has been demonstrated to induce mutations in mitochondrial DNA, production of ROS and lipid peroxidation [52]. Moreover, the NLRP3 inflammasome senses mitochondrial dysfunction via accumulation of ROS and reduced levels of autophagy potentiating chronic inflammation in RA [53]. In early and established phases of RA endothelial dysfunction is apparent [47]. Chondrocytes adapt to hypoxic conditions, producing ROS via oxygen fluctuation resulting in ischemia-reperfusion injury [33].